ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – ...

(RTTNews) - Alumis Inc. (ALMS), Friday has announced that it will present positive 52-week data from its Phase 2 open-label extension or OLE study of ESK-001, an oral TYK2 inhibitor, at the 2025 ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, ...

Their pipeline, supported by a proprietary precision data analytics platform, includes ESK-001 and other preclinical programs targeting a range of immune-mediated diseases. The company ...